Prevalence and trends of polypharmacy in U.S.adults,1999-2018  

作　　者：Xiaowen Wang Keyang Liu Kokoro Shirai Chengyao Tang Yonghua Hu Ying Wang Yuantao Hao Jia-Yi Dong 

机构地区：[1]Center for Public Health and Epidemic Preparedness and Response,Peking University,Beijing 100191,China [2]Key Laboratory of Epidemiology of Major Diseases(Peking University),Ministry of Education,Beijing,China [3]Public Health,Department of Social Medicine,Osaka University Graduate School of Medicine,Osaka 5650871,Japan [4]Department of Epidemiology and Biostatistics,School of Public Health,Peking University Health Science Center,Beijing 100191,China [5]Medical Informatics Center,Peking University Health Science Center,Beijing 100191,China [6]Department of Medical Statistics,School of Public Health,Sun Yat-Sen University,Guangzhou 510080,China

出　　处：《Global Health Research and Policy》2023年第1期284-292,共9页全球健康研究与政策（英文）

基　　金：supported by the National key research and development program of China(grant number 2022YFC3600804 to Y.Hao);China Postdoctoral Science Foundation(grant number 2023M730113 to X.Wang).

摘　　要：Background Polypharmacy is one of the most important health issues for its potential impacts on disease burden and healthcare costs.The aim of this study was to update a comprehensive picture of prevalence and trends in polypharmacy over 20 years in U.S.adults.Methods Participants included 55,081 adults aged≥20 from the National Health and Nutrition Examination Survey,January 1,1999,through December 31,2018.The simultaneously use of≥5 drugs in one individual was defined as polypharmacy.National prevalence and trends in polypharmacy were evaluated among U.S.adults within different demo-socioeconomic status and pre-existing diseases.Results From 1999-2000 to 2017-2018,the overall percentages of adults with polypharmacy remained on the rise,increasing from 8.2%(7.2-9.2%)to 17.1%(15.7-18.5%)(average annual percentage change[AAPC]=2.9%,P=.001).The polypharmacy prevalence was considerably higher in the elderly(from 23.5%to 44.1%),in adults with heart disease(from 40.6%to 61.7%),and in adults with diabetes(from 36.3%to 57.7%).Also,we observed a greater increase rate of polypharmacy in men(AAPC=4.1%,P<.001),in the Mexican American(AAPC=6.3%,P<.001),and in the non-Hispanic Black(AAPC=4.4%,P<.001).Conclusions From 1999-2000 to 2017-2018,the prevalence of polypharmacy is continually increasing in U.S.adults.The polypharmacy was especially higher in the older,in patients with heart disease,or diabetes.The high prevalence urges the healthcare providers and health policymakers to manage polypharmacy among specific population groups.

关 键 词：POLYPHARMACY National Health and Nutrition Examination Survey NHANES Trends PREVALENCE MEDICATION 

分 类 号：R57[医药卫生—消化系统]